Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons
Jie Sun, Xiao-Min Lin, Dan-Hua Lu, Meng Wang, Kun Li, Sheng-Rong Li, Zheng-Qiu Li, Cheng-Jun Zhu, Zhi-Min Zhang, Chang-Yu Yan, Ming-Hai Pan, Hai-Biao Gong, Jing-Cheng Feng, Yun-Feng Cao, Feng Huang, Wan-Yang Sun, Hiroshi Kurihara, Yi-Fang Li, Wen-Jun Duan, Gen-Long Jiao, Li Zhang, Rong-Rong He
Jie Sun, Xiao-Min Lin, Dan-Hua Lu, Meng Wang, Kun Li, Sheng-Rong Li, Zheng-Qiu Li, Cheng-Jun Zhu, Zhi-Min Zhang, Chang-Yu Yan, Ming-Hai Pan, Hai-Biao Gong, Jing-Cheng Feng, Yun-Feng Cao, Feng Huang, Wan-Yang Sun, Hiroshi Kurihara, Yi-Fang Li, Wen-Jun Duan, Gen-Long Jiao, Li Zhang, Rong-Rong He
View: Text | PDF | Corrigendum
Research Article Cell biology Neuroscience

Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons

  • Text
  • PDF
Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the gradual loss of midbrain dopaminergic neurons in association with aggregation of α-synuclein. Oxidative damage has been widely implicated in this disease, though the mechanisms involved remain elusive. Here, we demonstrated that preferential accumulation of peroxidized phospholipids and loss of the antioxidant enzyme glutathione peroxidase 4 (GPX4) were responsible for vulnerability of midbrain dopaminergic neurons and progressive motor dysfunctions in a mouse model of PD. We also established a mechanism wherein iron-induced dopamine oxidation modified GPX4, thereby rendering it amenable to degradation via the ubiquitin-proteasome pathway. In conclusion, this study unraveled what we believe to be a novel pathway for dopaminergic neuron degeneration during PD pathogenesis, driven by dopamine-induced loss of antioxidant GPX4 activity.

Authors

Jie Sun, Xiao-Min Lin, Dan-Hua Lu, Meng Wang, Kun Li, Sheng-Rong Li, Zheng-Qiu Li, Cheng-Jun Zhu, Zhi-Min Zhang, Chang-Yu Yan, Ming-Hai Pan, Hai-Biao Gong, Jing-Cheng Feng, Yun-Feng Cao, Feng Huang, Wan-Yang Sun, Hiroshi Kurihara, Yi-Fang Li, Wen-Jun Duan, Gen-Long Jiao, Li Zhang, Rong-Rong He

×

Figure 1

Ferroptosis pathway is involved in PD progression in SNCAA53T transgene mice.

Options: View larger image (or click on image) Download as PowerPoint
Ferroptosis pathway is involved in PD progression in SNCAA53T transgene ...
Disordered motor coordination was evaluated in 13-month-old SNCAA53T mice using the rotarod test (A, the time latency to drop from the rotarod) and pole climbing (B, the time latency to reach the bottom of the pole). WT mice were used as controls. Significance was determined by 2-way repeated measures ANOVA (n = 5). (C) Immunofluorescence of substantia nigra sections (dotted area) labeled with TH antibody (red) and DAPI (blue). Scale bar: 200 μm. (D) Western blotting (left) and quantitative analysis (right) of 4-HNE expression in midbrain. (E) MDA, (F) iron, and (G) glutathione (GSH) in midbrain were measured (n = 5). The phospholipids in midbrain were isolated and detected by LC-MS/MS (n = 4). Data of phospholipids were extracted and displayed as (H) principal component analysis (PCA) and (I) volcano plots showing the fold changes (X-axis) versus significance (Y-axis). (J) Ferroptosis-related genes were detected by qPCR assay and relative expressions were displayed as a heatmap. Slc7a11, solute carrier family 7 member 11; Gpx4, glutathione peroxidase 4; Pla2g6, phospholipase A2 group VI; Alox5/12/15, arachidonate 5/12/15-lipoxygenase; Tfrc, transferrin receptor; Ncoa4, nuclear receptor coactivator 4; Lpcat3, lyso-PC acyltransferase 3; Ptgs2, prostaglandin-endoperoxide synthase 2; Acsl4, acyl-CoA synthetase long chain family member 4; Dmt1, ferrous ion membrane transport protein DMT1. (K) IHC of midbrain sections labeled with GPX4 and 4-HNE antibodies and hematoxylin. IHC magnification (top) and IHC score (bottom). Scale bar: 50 μm. (L) Western blotting (top) and quantitative analysis (bottom) of GPX4 and TFRC expression in midbrain, cortex, and hippocampus, respectively. (M) MDA level was measured in the cortex and hippocampus, respectively (n = 5). All data represent mean ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001, by independent-samples t-test.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts